VistaGen Therapeutics Inc [VTGN] stock is trading at $5.28, up 15.54%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The VTGN shares have gain 25.27% over the last week, with a monthly amount glided 1.34%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 11, March 2024, Vistagen to Present at Stifel 2024 Virtual CNS Days. In a post published today on Yahoo Finance, Vistagen (Nasdaq: VTGN), a biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders, today announced that company management will present and host one-on-one meetings during the Stifel 2024 Virtual CNS Days taking place March 19 to 20, 2024.
From an analyst’s perspective:
VistaGen Therapeutics Inc [NASDAQ: VTGN] stock has seen the most recent analyst activity on December 07, 2023, when Jefferies upgraded its rating to a Buy but kept the price target unchanged to $15 for it. Previously, Maxim Group upgraded its rating to Buy on August 07, 2023, and kept the price target unchanged to $30. On July 22, 2022, downgrade downgraded it’s rating to Mkt Perform. Robert W. Baird downgraded its rating to a Neutral. Jefferies downgraded its rating to a Hold. Robert W. Baird started tracking with a Outperform rating for this stock on May 20, 2021, and assigned it a price target of $9. In a note dated February 18, 2021, Jefferies initiated an Buy rating and provided a target price of $6 on this stock.
VistaGen Therapeutics Inc [VTGN] stock has fluctuated between $1.62 and $24.71 over the past year. Currently, Wall Street analysts expect the stock to reach $6 within the next 12 months. VistaGen Therapeutics Inc [NASDAQ: VTGN] shares were valued at $5.28 at the most recent close of the market. An investor can expect a potential return of 13.64% based on the average VTGN price forecast.
Analyzing the VTGN fundamentals
VistaGen Therapeutics Inc [NASDAQ:VTGN] reported sales of 1.04M for the trailing twelve months, which represents a growth of 129.06%. Gross Profit Margin for this corporation currently stands at 0.25% with Operating Profit Margin at -32.53%, Pretax Profit Margin comes in at -30.76%, and Net Profit Margin reading is -30.77%. To continue investigating profitability, this company’s Return on Assets is posted at -0.24, Equity is -0.72 and Total Capital is -0.27. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.02.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 4.69 points at the first support level, and at 4.10 for the second support level. However, for the 1st resistance point, the stock is sitting at 5.77, and for the 2nd resistance point, it is at 6.26.
VistaGen Therapeutics Inc [VTGN] reported earnings per share of -$0.22 for its fiscal quarter that ended on 12/30/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.3/share, meaning a difference of $0.08 and a surprise factor of 26.70%. By comparison, the stated earnings for the previous quarter ended on 9/29/2023 were -$0.66 per share as compared to estimates of -$0.68 per share, a difference of $0.02 representing a surprise of 2.90%.
Ratios To Look Out For
For context, VistaGen Therapeutics Inc’s Current Ratio is 30.75. Also, the Quick Ratio is 30.75, while the Cash Ratio stands at 30.39. Considering the valuation of this stock, the price to sales ratio is 137.23, the price to book ratio is 1.16.
Transactions by insiders
Recent insider trading involved COMMODORE CAPITAL LP, 10% Owner, that happened on Aug 07 ’23 when 0.78 million shares were purchased.
